The Effects of Bupropion Alone and Combined With Naltrexone on Blood Pressure and Crp Concentration: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials Publisher Pubmed



Jiang Q¹ ; Velu P² ; Sohouli MH³ ; Ziamanesh F⁴ ; Shojaie S⁴ ; Fatahi S⁵ ; Li Q⁶
Source: European Journal of Clinical Investigation Published:2024

Abstract

Background: Considering the conflicting effects of bupropion on parameters related to cardiovascular system including blood pressure and inflammation, in this meta-analysis study, we investigated the effects of this drug alone or in combination with naltrexone on systolic (SBP) and diastolic blood pressure (DBP) and C-reactive protein (CRP). Methods: Scopus, PubMed/Medline, Web of Science and Embase databases were searched using standard keywords to identify all controlled trials investigating effects of bupropion alone and combined with naltrexone on the BP and CRP. Pooled weighted mean difference and 95% confidence intervals (CIs) were achieved by random-effects model analysis for the best estimation of outcomes. Results: The pooled findings showed that that bupropion alone or in combination with naltrexone would significantly increase SBP (weighted mean difference (WMD): 1.34 mmHg, 95% CI: 0.38–2.29) and DBP (WMD: 0.93 mmHg, 95% CI 0.88–0.99) as well as decrease CRP (WMD: −0.89 mg/L, 95% CI −1.09 to −0.70). The findings of the subgroup also show the greater effect of bupropion on blood pressure (SBP and DBP) increase in a dose greater than 360 mg and a duration of intervention less equal to 26 weeks. In addition, the subgroup analysis showed that changes in SBP after receiving bupropion together with naltrexone were more compared to bupropion alone. Conclusions: The addition of combination therapies such as bupropion and naltrexone can significantly improve CRP levels. However, its effect on blood pressure requires proper management of this drug. © 2023 Stichting European Society for Clinical Investigation Journal Foundation. Published by John Wiley & Sons Ltd.